Upcoming IPO | Yinuo Micro Pharmaceuticals: Clinical progress accelerates, but the funding challenges for innovative drugs under 18A remain.

In recent years, the Hong Kong stock market's 18A biotechnology sector has gradually entered a phase of differentiation. After an early period driven by innovative concepts that influenced valuations, the capital market is increasingly focusing on the clinical progress of core pipelines, the ability to commercialize, and the level of financial reserves. Against this backdrop, Yinuo Micropharmaceuticals, which specializes in oncolytic immunotherapy and engineered exosomes, has officially submitted its application for listing on the Hong Kong stock exchange, aiming to go public on the main board. Established in 2015 as an innovative drug company, Yinuo Micro has not chosen to compete in the fiercely competitive fields of PD-1, ADC, and other hot tracks. Instead, it has built its product pipeline around the niche of oncolytic viruses while simultaneously developing an engineered exosome platform, hoping to achieve long-term growth through a "dual-platform" model. In the current biopharmaceutical industry, facing dual challenges of capital winter and homogenized competition, Yinuo Micro's prospectus not only showcases its ambitious plans to tackle solid tumors and expand into the functional aesthetics market but also candidly presents the financial pain and liquidity concerns typically faced by a pre-commercial, research-driven pharmaceutical enterprise. Focusing on oncolytic immunotherapy, the company constructs a differentiated R&D system through its dual platforms. From a business structure perspective, Yinuo Micro has formed a development model centered on oncolytic immunotherapy, with engineered exosomes as its second growth curve. Among these, oncolytic immunotherapy is the strategic focus of the company and the primary source for future value realization. Reportedly, the company's independently developed core product MVR-T3011 is based on an HSV-1 viral vector. By integrating three mechanismstumor lysis, PD-1 antibody expression, and IL-12 expressionit not only directly kills tumor cells but also activates the body's immune system, thereby enhancing the therapeutic effect on solid tumors. Compared to traditional oncolytic virus products, its most significant feature lies in supporting multiple administration methods, including intratumoral injection, intravesical administration, and intravenous injection, making it possible for the product to cover more solid tumor indications in the future. As of the last practical date, the company has established a research system covering multiple indications, including bladder cancer and head and neck squamous cell carcinoma, around MVR-T3011. Among these, high-risk non-muscle invasive bladder cancer (NMIBC) has become the currently prioritized commercialization direction. The prospectus shows that the company has initiated a Phase II clinical trial in the United States for NMIBC patients who do not respond to BCG treatment and plans to further expand to BCG-nave patients and muscle-invasive bladder cancer (MIBC) indications, expecting to gradually cover the entire treatment market for bladder cancer. Meanwhile, the clinical study focused on head and neck squamous cell carcinoma has also been relaunched and has received FDA fast track designation, creating certain conveniences for future overseas registration and approval. Notably, the company has continuously adjusted its R&D resource allocation in recent years. Previously, the company had suspended some Phase IIa studies on melanoma and other indications not due to safety or efficacy issues, but rather for reasons of capital efficiency and commercial value, channeling R&D resources into bladder cancera field with higher unmet clinical needs and a relatively friendly competitive landscape. Besides oncolytic viruses, another significant layout of the company is the engineered exosome platform. Leveraging its independently developed OVPENS platform, the company is simultaneously developing multiple products for wound healing, pulmonary fibrosis, and the functional aesthetics field. Among these, some functional aesthetics products are expected to achieve commercialization through relatively mature registration pathways, providing the company with a certain source of cash flow, indicating that the company is not entirely reliant on the single pathway of innovative drug launches, but is aiming for a more balanced development model through different product types. However, compared to core innovative drug products, the revenue contributions from this portion of the business remain uncertain; its ultimate value still needs to be validated through commercialization. From the perspective of industry development trends, oncolytic viruses remain an important frontier in global innovative drug R&D. As tumor immunotherapy gradually enters the era of combination treatments, oncolytic viruses that possess both direct lytic and immune activation functions are garnering increasing attention from more pharmaceutical companies. However, compared to mature tracks such as PD-1 and CAR-T, the number of oncolytic virus products that have truly been commercialized globally remains quite limited, especially in the fields of bladder cancer and head and neck squamous cell carcinoma, where there is currently a lack of mature products. Thus, the track Yinuo Micro is in signifies both a significant market opportunity and a future that requires lengthy validation of clinical value. According to Frost & Sullivan data, the global oncolytic immunotherapy for bladder cancer is still primarily in the clinical development stage, with the company's core product among the top international contenders; however, there are still several key milestones that need to be overcome before true commercialization. Investing in R&D leads to clinical progress, while commercialization remains key to value realization. For innovative drug companies, financial statements often reflect the efficiency of R&D investment rather than traditional profitability. According to data disclosed in the prospectus, Yinuo Micro's overall operational characteristics in recent years fit the common patterns of 18A innovative drug companies in the Hong Kong stock market, namely, consistently maintaining high R&D investment, ongoing net cash outflows from operating activities, and relying on equity financing and partnership licensing to support R&D advancement. Among these, R&D investment has always been the companys largest cost expenditure. The prospectus indicates that from 2023 to 2025, the company's R&D expenditures are approximately 136 million yuan, 112 million yuan, and 112 million yuan respectively, maintaining an overall high level. Although the R&D expenses in 2024 are lower than in 2023, the main reason is not due to a reduction in R&D efforts but rather an adjustment in the pace of expenditures resulting from the completion of some clinical projects and resource reallocation. Structurally, the core product MVR-T3011 always occupies the majority of the R&D investment, with core product R&D costs accounting for approximately 79.2%, 67.7%, and 64.4% of total R&D investment from 2023 to 2025, showing that the company's resources remain highly concentrated on the core pipeline. This focused R&D strategy helps to enhance the efficiency of fund usage and reflects the company's desire to expedite the core product into later clinical stages and even commercialization. At the same time, the proportion of R&D expenses in total operating expenses is also showing a gradual decline, decreasing from 79.1% in 2023 to 56.9% in 2025. This shift does not indicate a weakening in the company's R&D efforts but rather reflects that as the company scales up, administrative management, clinical operations, and preparation costs are growing simultaneously. For an innovative drug company sprinting towards the capital markets, such a change in cost structure is quite common. However, in the long term, if clinical trials enter Phase III or even the commercialization preparation stage, the companys R&D expenditure may re-enter an upward cycle, and its funding needs will not significantly decline. In terms of revenue structure, Yinuo Micro has not yet formed stable product sales income, as total revenue mostly comes from partnership licensing and other operating revenues, resulting in substantial revenue fluctuations. In terms of profitability, the company is still in a continuous loss stage, with losses primarily stemming from ongoing R&D investments, clinical trial costs, and management expenses. For innovative drug companies, as long as core products are continually advanced and the capital chain remains stable, such phase losses are generally seen by the market as part of R&D investment. On the other hand, if future clinical progress falls short of expectations or if the financing environment changes, this long-term loss model could quickly operational pressure. It has been observed that global tumor immunotherapy continues to maintain rapid growth, with oncolytic viruses being a new generation of immunotherapy technology that has received consistent attention from major international pharmaceutical companies in recent years. As traditional PD-1 monotherapy gradually enters a highly competitive market, new therapies that can generate synergistic effects with immune checkpoint inhibitors are becoming key development directions in the industry. Yinuo Micro's core product simultaneously possesses three mechanisms: viral oncolysis, PD-1 antibody expression, and IL-12 immune activation, providing it with a certain differential advantage in terms of its technical route. If subsequent Phase II clinical trials can further validate its efficacy, the company is likely to share the growth opportunities brought by the expansion of the global bladder cancer and head and neck squamous cell carcinoma treatment markets. However, alongside opportunities, the company also faces multiple risks. First, the core product is still in the clinical development stage, with uncertainties surrounding subsequent clinical outcomes, regulatory approvals, and launch timelines. Any key trial that fails to meet its expected endpoints could impact the overall valuation logic. Moreover, global competition for innovative drugs continues to intensify, especially as technical routes in tumor immunotherapy are constantly evolving. If new methods emerge in the future that demonstrate better efficacy or lower costs, the competitiveness of the company's products may be weakened. At the same time, the commercialization of innovative drugs involves multiple links, such as medical insurance access, market promotion, and production ramp-up; even if the product ultimately obtains approval for launch, it will still need to undergo market validation. Overall, Yinuo Micro remains a typical R&D-focused innovative drug company, with its value being more established on future potential rather than present metrics. The company has built a relatively complete platform system around oncolytic immunotherapy and engineered exosomes, and the clinical progress of its core products in indications such as bladder cancer and head and neck squamous cell carcinoma gives it a certain degree of international competitive potential. Once MVR-T3011 can successfully complete critical clinical trials and achieve market approval, the company is expected to transition from a research enterprise that continuously relies on financing to an innovative drug enterprise with self-sustaining capabilities. Conversely, if clinical progress, financing pace, or commercialization advancement falls short of expectations, its long-term growth logic will still face significant uncertainties. In other words, Yinuo Micro's investment value is not only dependent on its technical platform but also on whether it can consistently deliver on critical clinical milestones in the coming years.